Efficacy of a new intravenous β2-adrenergic agonist (bedoradrine, MN-221) for patients with an acute exacerbation of asthma

Stacey L. House, Kazuko Matsuda, Geoffrey O'Brien, Malath Makhay, Yuichi Iwaki, Ian Ferguson, Luis M. Lovato, Lawrence M. Lewis

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Background Many patients with acute exacerbation of asthma are non-responders to inhaled β-adrenergic agonists. The goal of this study was to evaluate the safety and efficacy of intravenous bedoradrine (MN-221), a highly selective β2-adrenergic agonist, as adjunct to standard therapy in the management of patients with acute exacerbation of asthma who did not respond to standard therapy. Methods Patients (N = 167) received standard therapy and were randomized to either bedoradrine (1200 μg) or placebo. Safety and efficacy parameters were monitored hourly for 3 h, followed by a 24-h follow-up visit and an 8-day follow-up phone call. Change in %FEV1 from baseline to Hour 3 was the primary outcome. Secondary outcome measures included change in %FEV1 at 1 and 2 h, change in dyspnea score at 1, 2, and 3 h, treatment failure rate, defined as a combination of hospitalization on the index visit or return to the emergency department within 1 week, and safety monitoring. Results There was no significant difference in %FEV1 at 3 h between the 2 groups. The dyspnea scores were significantly improved for patients treated with bedoradrine compared to placebo (AUC0-2 h P < 0.005, AUC0-3 h P < 0.05). The safety profile for those treated with bedoradrine was consistent with the known mechanism of action of β-adrenergic agonists, and included both cardiovascular and metabolic effects. Conclusions Intravenous bedoradrine, in addition to standard therapy, did not significantly increase %FEV1 at 3 h, but it was associated with significantly improved dyspnea scores.

Original languageEnglish
Pages (from-to)1268-1273
Number of pages6
JournalRespiratory Medicine
Issue number10
StatePublished - Oct 1 2015


  • Asthma
  • Beta agonists
  • Emergency medicine
  • Pharmacotherapy


Dive into the research topics of 'Efficacy of a new intravenous β2-adrenergic agonist (bedoradrine, MN-221) for patients with an acute exacerbation of asthma'. Together they form a unique fingerprint.

Cite this